| Cheung, Angela M |
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures |
|
|
| Completed | 3 | 34 | Canada | Teriparatide 20 mcg, Brand name Forteo, Placebo | University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company | Non Displaced Atypical Femoral Fractures | 12/21 | 12/22 | | |
| Completed | 3 | 410 | Europe, Canada, US, RoW | Albutein 20% Injectable Solution, Standard medical treatment | Grifols Therapeutics LLC, Instituto Grifols, S.A. | Decompensated Cirrhosis and Ascites | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 238 | Europe, Canada, Japan, US, RoW | Linerixibat, Placebo | GlaxoSmithKline | Pruritus | 10/24 | 01/25 | | |
| Active, not recruiting | 2/3 | 272 | Canada | LAU-7b for 3 cycles, fenretinide, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles, sugar pill | Laurent Pharmaceuticals Inc. | Long COVID | 08/24 | 10/24 | | |
RECLAIM - HBOT, NCT06452095: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition |
|
|
| Not yet recruiting | 2/3 | 120 | NA | Hyperbaric Oxygen therapy | University Health Network, Toronto | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | 12/28 | 12/28 | | |
| Suspended | 2/3 | 460 | Canada | Ibudilast, MN-166, Pentoxifylline, Placebo | University Health Network, Toronto | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | 05/26 | 12/26 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
Hi-OXSR, NCT06379620: Pilot Open Label Use of the for the Treatment of Post COVID-19 Cognitive Dysfunction |
|
|
| Completed | 1 | 37 | Canada | Hi-OxSR Sequential Rebreathing mask (oxygen concentrator) | University Health Network, Toronto | Post COVID-19 Condition | 03/24 | 03/24 | | |
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) |
|
|
| Terminated | 1 | 16 | Europe, Canada, US, RoW | SAR439459, Placebo | Sanofi | Osteogenesis Imperfecta | 11/24 | 11/24 | | |
NCT01155245: Teriparatide (PTH) and Bone Strength in Postmenopausal Women |
|
|
| Active, not recruiting | N/A | 60 | Canada | Forteo | University Health Network, Toronto, Eli Lilly and Company | Osteoporosis | 01/24 | 01/25 | | |
NCT01747304: Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs |
|
|
| Recruiting | N/A | 500 | Canada | DXA Se femur scans (previously called IVA femur), SF Femur scans | University Health Network, Toronto | Atypical Femur Fracture | 12/24 | 12/25 | | |
NCT01155232: Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis |
|
|
| Recruiting | N/A | 100 | Canada | Teriparatide, Teriparatide is a section of the parathyroid hormone (PTH) given by injection., The drug is marketed by Eli Lilly under the name of Forteo | University Health Network, Toronto | Osteoporosis | 01/25 | 01/26 | | |
| Recruiting | N/A | 300 | Canada | | University Health Network, Toronto | Atypical Femur Fracture, Atypical Subtrochanteric Fracture, Osteoporosis With AFf | 12/25 | 12/26 | | |
NCT04110795: Personalizing Osteoporosis Care: Clinical & Genetic Risk Factors for AFFs |
|
|
| Active, not recruiting | N/A | 1200 | Canada | No Intervention | University Health Network, Toronto, Canadian Institutes of Health Research (CIHR) | Atypical Femur Fracture | 12/25 | 12/27 | | |
NCT05541432: Finding the Optimal Resistance Training Intensity For Your Bones |
|
|
| Recruiting | N/A | 324 | Canada | Supervised strength training (group 1), Supervised strength training (group 2), Home exercise | University of Waterloo, Canadian Institutes of Health Research (CIHR), University of Saskatchewan, University Health Network, Toronto | Osteoporosis, Osteopenia | 09/26 | 09/26 | | |
| Recruiting | N/A | 2500 | Canada | Observational; no intervention | University Health Network, Toronto | Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome | 12/28 | 12/28 | | |
| Juni, Peter |
| Suspended | 2/3 | 460 | Canada | Ibudilast, MN-166, Pentoxifylline, Placebo | University Health Network, Toronto | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | 05/26 | 12/26 | | |
| Cowan, Juthaporn |
| Suspended | 2/3 | 460 | Canada | Ibudilast, MN-166, Pentoxifylline, Placebo | University Health Network, Toronto | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | 05/26 | 12/26 | | |
| Active, not recruiting | 2 | 669 | Canada | mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine | Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre | COVID-19 | 11/24 | 02/25 | | |
| Tomlinson, George |
| Suspended | 2/3 | 460 | Canada | Ibudilast, MN-166, Pentoxifylline, Placebo | University Health Network, Toronto | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | 05/26 | 12/26 | | |
NCT03315247: Tele-CBT Following Bariatric Surgery: Randomized Control Trial |
|
|
| Completed | N/A | 306 | Canada | Telephone-Based CBT, Tele-CBT | University Health Network, Toronto | Obesity | 01/24 | 01/24 | | |
TOPCOP3, NCT05582772: TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer |
|
|
| Recruiting | N/A | 168 | Canada | GA+M Intervention, Geriatric assessment and management, RSM intervention, Remote symptom monitoring, GA+RSM intervention, Geriatric assessment and remote symptom monitoring | University Health Network, Toronto | Metastatic Prostate Cancer | 02/27 | 02/27 | | |
| Cohen, Suzanne |
| Suspended | 2/3 | 460 | Canada | Ibudilast, MN-166, Pentoxifylline, Placebo | University Health Network, Toronto | Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19 | 05/26 | 12/26 | | |
